Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7061-7070 Newer>

The Motley Fool January 7, 2011 Brian Orelli	Dendreon Heads Across the Pond A pathway to Provenge approval in the EU.
The Motley Fool January 7, 2011 Brian Orelli	A Biotech Roller Coaster Lexicon is back on the upswing.
The Motley Fool January 7, 2011 Seth Jayson	Here's How Steris Is Making You So Much Cash Steris's issue isn't questionable cash flow boosts, but items in that suspect group that reduced cash flow.
BusinessWeek January 6, 2011 Justin Blum	Why Medicare Can't Catch the Fraudsters One provider's claims were paid despite unusual billing patterns
The Motley Fool January 6, 2011 Brian Orelli	$145 Million Down; Billions to Go Seattle Genetics signs up another partner.
The Motley Fool January 6, 2011 Seth Jayson	Should You Get Out of Immucor Before Next Quarter? Is Immucor sending any potential warning signs? Take a look at the chart below, which plots revenue growth against AR growth, and DSO.
The Motley Fool January 5, 2011 Brian Orelli	Spectrum Pharma Jumps in With the Big Dogs Spectrum is developing biosimilars.
The Motley Fool January 5, 2011 Brian Orelli	Pfizer Goes Back for Seconds Headed back for more from Santaris. The company is putting up just $14 million for expanded access to Santaris' LNA technology.
The Motley Fool January 5, 2011 Steve Hall	Five Technology Trends to Watch in 2011 The big moves in 2011 from various technology industries.
The Motley Fool January 5, 2011 Seth Jayson	Why Wall Street Should Love C.R. Bard's Earnings With 11.4% of operating cash flow coming from questionable sources, C.R. Bard investors should take a closer look at the underlying numbers.
<Older 7061-7070 Newer> Return to current articles.